<DOC>
	<DOCNO>NCT01320735</DOCNO>
	<brief_summary>The objective study describe treatment pattern leuprorelin 2 year use intermittent , adjuvant regimen participant advanced prostate cancer ( PCa )</brief_summary>
	<brief_title>Observational Program Assess Use Intermittent Adjuvant Deprivation Therapy With Leuprorelin ( Lucrin Depot ) Patients With Advanced Prostate Cancer ( PCa ) Russia</brief_title>
	<detailed_description>Participants start hormone treatment Leuprorelin 3.75 mg every 28 day , subcutaneously ( SC ) intramuscularly ( IM ) . Duration induction therapy least 6 month ( 6-9 month ) PSA testosterone level measure every 3 month . When PSA decrease great 90 % baseline ( PSA le 10 ng/ml ) become low 4.0 ng/ml ( 2 consecutive measurement make least 2 week apart ) participant include intermittent hormone therapy regimen group ( IAD ) . Participants PSA decrease achieve great 90 % less equal 4.0 ng/ml give either continuous hormone therapy ( CAD ) chemotherapy . Therapy stop participant PSA decrease great 90 % baseline value less 4.0 ng/ml 6-9 month continuous hormone therapy . PSA testosterone measure every 4 week . If PSA become great equal 10.0 ng/ml , hormone therapy resume PSA le 4.0 ng/ml 2 consecutive measurement make least 2 week apart . Duration hormonal therapy cycle least 3 month . Then intermittent treatment perform accord similar scheme . PSA testosterone level determine every 12 week hormone therapy administer every 4 week stop . The treatment carry 2 year Hormone Refractory Prostate Cancer ( HRPC ) develop .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>1 . Histologically confirm advanced PCa meeting follow criterion : 1 . Any Tumor , Node 1 , Metastasis 0 2 . Any Tumor , Node 0 , Metastasis 1 [ accord Tumor Node Metastasis classification 2009 ] 2 . Participants plan administration leuprorelin 3 . World Health Organization status 01 4 . Life expectancy least 2 year 1 . Contraindications administration leuprorelin : 1 . Hypersensitivity Leuprorelin similar product protein origin excipients drug product composition 2 . Surgical castration 2 . Hormonerefractory PCa 3 . Presence another malignant tumor ( except skin cancer ) 4 . Previous administration hormone therapy gonadotropinreleasing hormone agonist antiandrogens 5 . Previous administration radiotherapy chemotherapy course within 1 month 6 . Testosterone level le equal 50 ng/dl ( less equal 1.7 mmol/l ) time inclusion 7 . Extremely high level PSA ( great equal 1000 ng/ml ) 8 . Other severe disease stage decompensation 9 . Other contraindication , make participant 's participation impossible ( investigator judgment ) 10 . Previous enrollment present program</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Lucrin Depot</keyword>
	<keyword>intermittent adjuvant regimen</keyword>
	<keyword>advanced prostate cancer</keyword>
	<keyword>Leuprorelin</keyword>
</DOC>